newsfilter
← Latest News
GlobeNewswire·

IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update

- Enrollment target exceeded in aplitabart randomized colorectal cancer clinical trial - - Enrollment completed in first dose cohort in imvotamab rheumatoid arthritis clinical trial - MOUNTAIN VIEW, Calif., May 08,